Dodd Peter J, Osman Muhammad, Cresswell Fiona V, Stadelman Anna M, Lan Nguyen Huu, Thuong Nguyen Thuy Thuong, Muzyamba Morris, Glaser Lisa, Dlamini Sicelo S, Seddon James A
School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom.
Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Stellenbosch, South Africa.
PLOS Glob Public Health. 2021 Dec 8;1(12):e0000069. doi: 10.1371/journal.pgph.0000069. eCollection 2021.
Tuberculous meningitis (TBM) is the most lethal form of tuberculosis. The incidence and mortality of TBM is unknown due to diagnostic challenges and limited disaggregated reporting of treated TBM by existing surveillance systems. We aimed to estimate the incidence and mortality of TBM in adults (15+ years) globally. Using national surveillance data from Brazil, South Africa, the United Kingdom, the United States of America, and Vietnam, we estimated the fraction of reported tuberculosis that is TBM, and the case fatality ratios for treated TBM in each of these countries. We adjusted these estimates according to findings from a systematic review and meta-analysis and applied them to World Health Organization tuberculosis notifications and estimates to model the global TBM incidence and mortality. Assuming the case detection ratio (CDR) for TBM was the same as all TB, we estimated that in 2019, 164,000 (95% UI; 129,000-199,000) adults developed TBM globally; 23% were among people living with HIV. Almost 60% of incident TBM occurred in males and 20% were in adults 25-34 years old. 70% of global TBM incidence occurred in Southeast Asia and Africa. We estimated that 78,200 (95% UI; 52,300-104,000) adults died of TBM in 2019, representing 48% of incident TBM. TBM case fatality in those treated was on average 27%. Sensitivity analysis assuming improved detection of TBM compared to other forms of TB (CDR odds ratio of 2) reduced estimated global mortality to 54,900 (95% UI; 32,200-77,700); assuming instead worse detection for TBM (CDR odds ratio of 0.5) increased estimated mortality to 125,000 (95% UI; 88,800-161,000). Our results highlight the need for improved routine TBM monitoring, especially in high burden countries. Reducing TBM incidence and mortality will be necessary to achieve the End TB Strategy targets.
结核性脑膜炎(TBM)是结核病最致命的形式。由于诊断方面的挑战以及现有监测系统对接受治疗的TBM的分类报告有限,TBM的发病率和死亡率尚不清楚。我们旨在估计全球成年人(15岁及以上)中TBM的发病率和死亡率。利用来自巴西、南非、英国、美国和越南的国家监测数据,我们估计了报告的结核病中TBM所占的比例,以及这些国家中接受治疗的TBM的病死率。我们根据一项系统评价和荟萃分析的结果对这些估计值进行了调整,并将其应用于世界卫生组织的结核病通报和估计数,以模拟全球TBM的发病率和死亡率。假设TBM的病例检出率(CDR)与所有结核病相同,我们估计在2019年,全球有16.4万(95%不确定区间;12.9万 - 19.9万)名成年人患上了TBM;其中23%为艾滋病毒感染者。几乎60%的新发TBM病例发生在男性中,20%发生在25 - 34岁的成年人中。全球70%的TBM发病率发生在东南亚和非洲。我们估计在2019年有7.82万(95%不确定区间;5.23万 - 10.4万)名成年人死于TBM,占新发TBM病例的48%。接受治疗的TBM患者的病死率平均为27%。敏感性分析假设与其他形式的结核病相比,TBM的检测有所改善(CDR比值比为2),则估计的全球死亡率降至5.49万(95%不确定区间;3.22万 - 7.77万);相反,假设TBM的检测更差(CDR比值比为0.5),则估计的死亡率增至12.5万(95%不确定区间;8.88万 - 16.1万)。我们的结果凸显了改善TBM常规监测的必要性,尤其是在高负担国家。降低TBM的发病率和死亡率对于实现终止结核病战略目标至关重要。